Results 131 to 140 of about 34,942 (245)

Targeting hexokinase 2 to induce breast cancer cell senescence

British Journal of Pharmacology, EarlyView.
Background and Purpose Hexokinase 2 (HK2) is a key enzyme linked to high tumour cell proliferation. Its inhibitors such as 3‐bromopyruvic acid (3‐BP) induce cancer cell death, highlighting HK2 modulation as potential anti‐cancer treatment. However, standard chemotherapies often cause the emergence of senescent cancer cells, which goes along with cell ...
Helmut Bischof, Katarina Cisarova, Sandra Burgstaller, Mia Schwerer, Markus Absenger‐Novak, Philipp J. Jost, Roland Malli, Wolfgang F. Graier, Robert Lukowski   +8 more
wiley   +1 more source

Per Med [PDF]

AimTo describe the knowledge and attitudes of clinicians participating in a large pharmacogenomics implementation program.Materials & methodsSemi-structured interviews with 15 physicians and nurse practitioners were conducted.ResultsThree categories of ...

core  

Emerging ethical issues in pharmacogenomics [PDF]

, 2001
abstrac
Freund, Carol L., Wilfond, Benjamin S.
core  

Peripheral κ opioid receptor in pain and inflammation: From molecular signalling and gene expression to drug discovery

British Journal of Pharmacology, EarlyView.
The κ opioid receptor (κ receptor, KOR) is a G protein‐coupled receptor with well established roles in analgesia and immune modulation. Although historically studied primarily in the central nervous system (CNS), growing evidence indicates that κ signalling in peripheral tissues plays an important role in regulating pain, inflammation and immune ...
Rumsha Khan, Elena C. A. Becker, Boglarka B. Bata, Christian W. Gruber   +3 more
wiley   +1 more source

Pharmacogenomics: today, tomorrow and beyond [PDF]

, 1999
Pharmacogenomics is today’s hot topic in biotechnology. In 1996 the word did not even exist; now international pharmacogenomics meetings are held monthly, and articles appear weekly in scientific journals ind the popular press. In this Viewpoint article,
Bhagat, K.
core  

First‐In‐Human Study: Dose Expansion of E7130 in Urothelial Carcinoma and Squamous Cell Carcinoma of the Head and Neck

Cancer Science, EarlyView.
The dose escalation part of the first‐in‐human study of E7130 in patients with advanced solid tumors determined the Recommended Phase 2 Dose of E7130 (480 μg/m2 Q3W). The dose expansion part (presented here) examined safety/preliminary efficacy in patients with squamous cell carcinoma of the head and neck and urothelial carcinoma.
Nobuaki Matsubara, Ken Saijo, Yasushi Shimizu, Susumu Okano, Kenji Nakano, Naoki Nishio, Tomoyuki Otsuka, Hirofumi Kuno, Takuma Miura, Tomoki Kubota, Hiroki Ikezawa, Yuko Umetsu, Ken Ito, Abraham Apfel, Yuanqing Ye, Yoshitaka Honma   +15 more
wiley   +1 more source

Variations in the Wnt/β-catenin pathway key genes as predictors of cervical cancer susceptibility [corrigendum] [PDF]

, 2020
Pharmacogenomics and Personalized Medicine
core   +2 more sources

Pharmacogenomics: today, tomorrow and beyond [PDF]

, 2019
Pharmacogenomics is today’s hot topic in biotechnology. In 1996 the word did not even exist; now international pharmacogenomics meetings are held monthly, and articles appear weekly in scientific journals ind the popular press. In this Viewpoint article,
Bhagat, K.
core  

Dolutegravir population pharmacokinetics in racially, sex‐ and age‐diverse and antiretroviral therapy‐experienced adults with HIV in the United States

HIV Medicine, EarlyView.
Abstract Objectives Dolutegravir (DTG) has been associated with weight gain in women with HIV, Black people with HIV and people with HIV60 years. This study aimed to characterise DTG population pharmacokinetics (PopPK) in a diverse population including these sub‐populations.
Adrian Khoei, Andrew Edmonds, Yen Chang, Catalina Ramirez, Mackenzie Vogan, Amanda Poliseno, Steven Wolinsky, Ken Ho, Todd T. Brown, Joseph B. Margolick, Jacquett Batson, Jennifer Hoffmann, Mark A. Marzinke, Mirjam‐Colette Kempf, Maria L. Alcaide, Joffi Effoe, Cecile D. Lahiri, Igho Ofotokun, Anandi N. Sheth, Stephen Gange, Audrey L. French, Bani Tamraz, Bradley E. Aouizerat, Phyllis C. Tien, Seble G. Kassaye, Jack DeHovitz, Kathryn Anastos, Kara W. Chew, Michelle Floris‐Moore, Julie B. Dumond   +29 more
wiley   +1 more source

Building a precision therapeutics program at a tertiary care children's hospital

Pediatric Investigation, EarlyView.
Luke Hamilton, Heidi Trinkman, Diana Carrasco, Kaitlin Smith, Kelly Vallance, Alejandra Dominguez, Danielle Miller, Megan Gibbs, Anish Ray   +8 more
wiley   +1 more source